Role of Inflammasomes in COVID-19 Disease

NCT04385017 | Completed

• 1 other identifier: 20-PP-07
• Study Type: interventional
• Target: 99
• Locations: 1 country
• Sites: 2

Brief Summary

As of March 25, 2020, 414,179 cases and 18,440 deaths secondary to Coronavirus 2019 disease (COVID-19) have been reported worldwide. The unfavorable course of the patients is characterized on the immunological level by an intense pro-inflammatory response which can go as far as a cytokinic storm. This pandemic affects a naive world population from an immunological point of view with respect to SARS-CoV-2 responsible for COVID-19. The evolution is favorable without hospitalization in almost 85% of cases. Among patients hospitalized for pneumonia, some will not require ventilatory support while others will need intensive care. To date, two main types of unfavorable evolution have been described. The first is a bi-phasic evolution beginning with a paucisymptomatic form which is worsened secondarily with respiratory distress associated with a decrease in the viral load in the airways. The second is associated with persistent high viral loads in the airways and detection of the virus in the blood. These different clinical profiles could depend on the quantitative and qualitative response of the innate immune system. At the early stage of a viral infection the innate immunity is capable of detecting certain conserved microbial patterns (PAMP, pathogen-associated molecular pattern) recognized by receptors dedicated to these patterns (PRR, pattern recognition receptor). This process allows to initiate the pro-inflammatory response via different signaling pathways. Activating multiprotein complexes called inflammasomes, which cause pro-IL-1β and pro-IL-18 to be transformed into active pro-inflammatory cytokines are one of these pathways. The central role of inflammasomes in the secretion of these pro-inflammatory cytokines deserves an in-depth study of their activation during COVID-19, whereas the inadequate inflammatory response appears to be the determining factor in the unfavorable development of patients. The objective of this project is to analyze the level of activation of the inflammasomes and then to search for inactivating or activating mutations among the genes which code for the proteins constituting the inflammasomes in Covid-19 patients. The identification of mutations in patients with a serious clinical presentation or even death would be followed by fundamental work by analyzing in a cellular model the impact of these mutations on the secretion of IL-1β.

Conditions

COVID-19 by SARS-CoV-2 Infection

Outcome Measures

Primary Outcomes (1)

• Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19

  Percentage of immune cells with inflammasome positive labeling using flow cytometry in comparison to controls

  At inclusion

Secondary Outcomes (1)

• Genes nucleoside polymorphism analysis

  At inclusion

Study Arms (1)

DNA from monocytes

OTHER

It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing

Other: COVID-19 patients

Interventions

COVID-19 patients OTHER

It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing

DNA from monocytes

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age above 18 years old. SARS-CoV-2 infection confirmed by RT PCR or by serology Hospitalised patients with less than 14 days of COVID-19 symptoms. Date of first symptom being defined as to the date of one of the following symptoms : cough, dyspnea, fever above 38 °C, anosmia, dysgeusia or ageusia, chilblain Lupus erythematous Women of fertile age using at least one contraceptive method Health insurance Written informed consent

You may not qualify if:

• Pregnant or breastfeeding female
• Human immunodeficiency virus infection with CD4 under 200 cell/mm3
• Aplasia
• at-risk patients (minor, patient under judicial protection or tutorship)

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (2)

Ch Cannes, Réanimation

Cannes, Alpes Maritimes, 06, France

Location

CHU de nice

Nice, Alpes-Maritimes, 06200, France

Location

Related Publications (1)

• Courjon J, Dufies O, Robert A, Bailly L, Torre C, Chirio D, Contenti J, Vitale S, Loubatier C, Doye A, Pomares-Estran C, Gonfrier G, Lotte R, Munro P, Visvikis O, Dellamonica J, Giordanengo V, Carles M, Yvan-Charvet L, Ivanov S, Auberger P, Jacquel A, Boyer L. Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity. Blood Adv. 2021 Mar 9;5(5):1523-1534. doi: 10.1182/bloodadvances.2020003918.

  PMID: 33683342 DERIVED

Study Officials

• COURJON Johan

  CHU de Nice, Infectiologie

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Patient with COVID-19 disease

Study Record Dates

• First Submitted: May 10, 2020
• First Posted: May 12, 2020
• Study Start: May 11, 2020
• Primary Completion: February 1, 2022
• Study Completion: December 30, 2022
• Last Updated: March 22, 2023

Record last verified: 2022-10

Locations

FR (2)